Phase II Evaluation of Recombinant Interferon-β (LFN-βser) in Patients with Diffuse Mesothelioma: A Southwest Oncology Group Study
- 1 January 1990
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Interferon Research
- Vol. 10 (5) , 531-534
- https://doi.org/10.1089/jir.1990.10.531
Abstract
Fourteen evaluable patients with diffuse malignant mesothelioma were treated with a once-a-day for 5 days out of 7 for 6 weeks regimen of recombinant interferon-β (IFN-βser). No responses were noted. The major toxicities included fever, chills, nausea, vomiting, and anorexia. IFN-βser at this dose and schedule does not appear to be an active single agent for patients with refractory malignant mesothelioma.Keywords
This publication has 8 references indexed in Scilit:
- Effect of Recombinant Interferon-βser on Primary Human Tumor Colony-Forming UnitsJournal of Interferon Research, 1988
- Malignant mesotheliomas and chemotherapyJournal of Surgical Oncology, 1980
- Malignant MesotheliomaNew England Journal of Medicine, 1980
- Pleural Mesothelioma: Clinical Features and Therapeutic ImplicationsAnnals of Internal Medicine, 1977
- Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.Thorax, 1976
- Solitary (Localized) Pleural MesotheliomaChest, 1971
- Relation between Exposure to Asbestos and MesotheliomaNew England Journal of Medicine, 1965
- LOCALIZED FIBROUS MESOTHELIOMA OF THE PLEURAJournal of Thoracic Surgery, 1952